A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms
Status:
Unknown status
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
The aim of this study is to investigate the clinical value of [18F]aluminum
fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide（18F-AlF-NOTA-octreotide ）
positron emission tomography / computed tomography (PET/CT) in patients with neuroendocrine
neoplasms (NENs).